Dclk1 distinguishes between tumor and normal stem cells in the intestine

Area of Science:

• Oncology
• Gastroenterology
• Stem Cell Biology

Background:

• Tumor stem cells (TSCs) are promising therapeutic targets, but effective therapies are limited.
• Existing TSC markers often overlap with normal stem cell (NSC) markers, risking damage to healthy tissues.
• Identifying TSC-specific markers is crucial for developing targeted cancer therapies.

Purpose of the Study:

• To investigate doublecortin-like kinase 1 (Dclk1) as a potential specific marker for intestinal tumor stem cells.
• To determine if Dclk1 marks normal intestinal stem cells or tumor stem cells.
• To evaluate the therapeutic potential of targeting Dclk1-positive cells in colorectal cancer models.

Main Methods:

• Utilized lineage-tracing experiments in Apc(Min/+) mice to track Dclk1-expressing cells.
• Performed specific ablation of Dclk1-positive cells within intestinal polyps.
• Assessed the impact of Dclk1-positive cell ablation on polyp regression and normal intestinal tissue integrity.

Main Results:

• Demonstrated that Dclk1 marks intestinal tumor stem cells (TSCs) responsible for tumor growth, not normal stem cells (NSCs).
• Showed that Dclk1-positive TSCs continuously produce tumor progeny in Apc(Min/+) mouse polyps.
• Confirmed that specific ablation of Dclk1-positive TSCs led to significant polyp regression.
• Observed no apparent damage to the normal intestinal tissue following Dclk1-positive TSC ablation.

Conclusions:

• Dclk1 is a specific marker for intestinal tumor stem cells, distinct from normal stem cells.
• Targeting Dclk1-positive tumor stem cells offers a promising therapeutic strategy for colorectal cancer.
• This approach holds potential for effective cancer treatment with minimal side effects on normal tissues.